Changchun High-Tech Industry (000661.SZ) subsidiary GenSci161 injection clinical trial application approved for acceptance.
Changchun High-Tech (000661.SZ) announced that its controlling subsidiary, Changchun JinSai Pharmaceutical Co., Ltd. (referred to as "JinSai Pharmaceutical"), has recently received the "Acceptance Notification" issued by the National Medical Products Administration. The application for the domestic production drug registration clinical trial of JinSai Pharmaceutical's GenSci161 injection has been accepted. GenSci161 injection is a Class 1 therapeutic biological product independently developed by JinSai Pharmaceutical and is intended for the treatment of connective tissue disease-related interstitial lung disease.
Changchun High-Tech Industry (000661.SZ) announced that its holding subsidiary, Changchun Jin Sai Pharmaceutical Co., Ltd. (referred to as "Jin Sai Pharmaceutical"), has received the "Acceptance Notification" approved and issued by the National Medical Products Administration. The application for the clinical trial registration of Jin Sai Pharmaceutical's GenSci161 injection for domestic production has been accepted. GenSci161 injection is a Class 1 therapeutic biological product independently developed by Jin Sai Pharmaceutical, intended for the treatment of interstitial lung disease associated with connective tissue diseases.
Related Articles
WS-SK TARGET (08427) released its annual results, reporting a loss attributable to shareholders of 1.927 million ringgit, reversing from a profit in the same period last year.
RUIHE DATA (03680) announced its interim results, with profit attributable to shareholders of 58.205 million yuan, a year-on-year increase of 34.78%.
Some directors and executives of Cashway Fintech (603106.SH) plan to reduce their holdings in the company.
WS-SK TARGET (08427) released its annual results, reporting a loss attributable to shareholders of 1.927 million ringgit, reversing from a profit in the same period last year.
RUIHE DATA (03680) announced its interim results, with profit attributable to shareholders of 58.205 million yuan, a year-on-year increase of 34.78%.
Some directors and executives of Cashway Fintech (603106.SH) plan to reduce their holdings in the company.
RECOMMEND
